DK551486D0 - Midler med forsinket frigivelse omfattende hydroxypropylcelluloseethere - Google Patents

Midler med forsinket frigivelse omfattende hydroxypropylcelluloseethere

Info

Publication number
DK551486D0
DK551486D0 DK551486A DK551486A DK551486D0 DK 551486 D0 DK551486 D0 DK 551486D0 DK 551486 A DK551486 A DK 551486A DK 551486 A DK551486 A DK 551486A DK 551486 D0 DK551486 D0 DK 551486D0
Authority
DK
Denmark
Prior art keywords
comprehensive
hydroxypropyl cellulose
cellulose ethers
delayed delivery
delayed
Prior art date
Application number
DK551486A
Other languages
English (en)
Other versions
DK175298B1 (da
DK551486A (da
Inventor
Daniel A Alderman
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25174902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK551486(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of DK551486D0 publication Critical patent/DK551486D0/da
Publication of DK551486A publication Critical patent/DK551486A/da
Application granted granted Critical
Publication of DK175298B1 publication Critical patent/DK175298B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • General Preparation And Processing Of Foods (AREA)
DK198605514A 1985-11-18 1986-11-18 Materialer med forsinket frigivelse omfattende hydroxypropylcelluloseethere DK175298B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79904485 1985-11-18
US06/799,044 US4704285A (en) 1985-11-18 1985-11-18 Sustained release compositions comprising hydroxypropyl cellulose ethers

Publications (3)

Publication Number Publication Date
DK551486D0 true DK551486D0 (da) 1986-11-18
DK551486A DK551486A (da) 1987-05-19
DK175298B1 DK175298B1 (da) 2004-08-16

Family

ID=25174902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198605514A DK175298B1 (da) 1985-11-18 1986-11-18 Materialer med forsinket frigivelse omfattende hydroxypropylcelluloseethere

Country Status (12)

Country Link
US (1) US4704285A (da)
EP (1) EP0223590B2 (da)
JP (1) JPH078809B2 (da)
KR (1) KR920000737B1 (da)
AT (1) ATE91232T1 (da)
AU (1) AU599058B2 (da)
BR (1) BR8606003A (da)
CA (1) CA1287582C (da)
DE (1) DE3688674T2 (da)
DK (1) DK175298B1 (da)
FI (1) FI90310C (da)
PH (1) PH23698A (da)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
EP0297866A3 (en) * 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
AU2252388A (en) * 1988-05-02 1989-11-29 Zila Pharmaceuticals Compositions and in situ methods for forming films on body tissue
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
NZ230763A (en) * 1988-09-27 1991-10-25 Takeda Chemical Industries Ltd Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5576306A (en) * 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5281584A (en) * 1992-02-28 1994-01-25 The Dow Chemical Company Effect of particle-size distribution of cellulose ethers on palatability of compositions
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
NZ255579A (en) * 1992-09-18 1996-03-26 Yamanouchi Pharma Co Ltd Sustained release hydrogel pharmaceutical formulation
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5728402A (en) * 1994-11-16 1998-03-17 Andrx Pharmaceuticals Inc. Controlled release formulation of captopril or a prodrug of captopril
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
FR2766708B1 (fr) * 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
FR2766707A1 (fr) * 1997-07-30 1999-02-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethyl-cellulose et/ou de l'ethylcellulose a titre d'agents desintegrants, et procede d'obtention
IN186245B (da) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
EP2332522A3 (en) 1998-03-19 2011-12-07 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
JP2000119181A (ja) 1998-10-06 2000-04-25 Kureha Chem Ind Co Ltd エスクレチン及びその誘導体の放出制御経口製剤
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
WO2000033818A1 (en) 1998-12-11 2000-06-15 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
US6284262B1 (en) 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
IN190974B (da) 1999-09-10 2003-09-06 Ranbaxy Lab Ltd
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
MXPA05004338A (es) * 2002-10-22 2005-06-22 Ranbaxy Lab Ltd Composiciones de liberacion sostenida que contienen alfuzosin.
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20040175423A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds
ITMI20031096A1 (it) * 2003-05-30 2004-11-30 Eurand Spa Microcapsule per coacervazione contenenti farmaco incorporato nel polimero di rivestimento
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1675576A1 (en) * 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
AU2005330504B2 (en) 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
DK2377557T3 (da) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Sammensætninger, der omfatter azelastin, og metoder til brug deraf
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
WO2007059047A2 (en) * 2005-11-11 2007-05-24 Chandran V Ravi Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
CN101420937B (zh) * 2006-04-12 2011-06-22 日本曹达株式会社 缓释性片剂的制造方法
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007137216A2 (en) * 2006-05-22 2007-11-29 Janssen Pharmaceutica, N.V. Gastroretentive sustained release formulations
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
JP5605365B2 (ja) 2009-08-31 2014-10-15 ゼリア新薬工業株式会社 経口腸管洗浄用錠剤
TR200908308A1 (tr) 2010-01-18 2011-08-22 Turgut İlaçlari A.Ş. Etodolak içeren sürekli salım tablet formulasyonu
CN103328007B (zh) 2010-09-16 2016-09-21 北卡罗来纳州大学查珀尔希尔分校 作为药物试剂、化学试剂和生物试剂的递送载剂和前药的不对称双官能甲硅烷基单体及其颗粒
JP2013087170A (ja) * 2011-10-17 2013-05-13 Nippon Soda Co Ltd ヒドロキシプロピルセルロース微粒子
US20150037428A1 (en) 2011-11-29 2015-02-05 The University Of North Carolina At Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2050701C3 (de) * 1969-10-17 1979-12-20 Shinetsu Chemical Co., Tokio Verwendung eines pulverförmigen Celluloseäthers als Hilfsstoff zur Herstellung von leicht zerfallbaren festen Arzneiformen
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
JPS4917565B1 (da) * 1970-12-29 1974-05-01
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
JPS5438167B2 (da) * 1974-04-27 1979-11-19
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS5163927A (en) * 1974-11-28 1976-06-02 Shinetsu Chemical Co Ketsugoseiryokonajozaihokaizaino seizohoho
JPS5474855A (en) * 1977-11-29 1979-06-15 Takeda Chem Ind Ltd Preparation of finely divided soluble cellulose derivative
US4269859A (en) * 1979-04-19 1981-05-26 Brown Company Cellulose floc granules and process
JPS5657719A (en) * 1979-10-16 1981-05-20 Asahi Chem Ind Co Ltd Preparation of pharmaceutical
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
JPS59193815A (ja) * 1983-04-15 1984-11-02 Daicel Chem Ind Ltd 錠剤の製法
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
IE59066B1 (en) * 1985-02-19 1993-12-15 Key Pharma Controlled release potassium chloride

Also Published As

Publication number Publication date
EP0223590B2 (en) 1996-09-11
JPH078809B2 (ja) 1995-02-01
KR870004710A (ko) 1987-06-01
FI864665A (fi) 1987-05-19
AU6504686A (en) 1987-05-21
DE3688674D1 (de) 1993-08-12
AU599058B2 (en) 1990-07-12
DE3688674T2 (de) 1993-10-14
FI864665A0 (fi) 1986-11-17
DK175298B1 (da) 2004-08-16
DK551486A (da) 1987-05-19
JPS62120323A (ja) 1987-06-01
ATE91232T1 (de) 1993-07-15
US4704285A (en) 1987-11-03
FI90310B (fi) 1993-10-15
KR920000737B1 (ko) 1992-01-21
PH23698A (en) 1989-09-27
FI90310C (fi) 1994-01-25
EP0223590A3 (en) 1987-11-25
EP0223590A2 (en) 1987-05-27
EP0223590B1 (en) 1993-07-07
CA1287582C (en) 1991-08-13
BR8606003A (pt) 1987-09-15

Similar Documents

Publication Publication Date Title
DK551486D0 (da) Midler med forsinket frigivelse omfattende hydroxypropylcelluloseethere
AU4989997A (en) Soluble form osmotic dose delivery system
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
SE8406081D0 (sv) Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
EA199900028A1 (ru) Быстроразлагаемая внутрибуккально таблетка
DE69031950D1 (de) Kleine partikeln enthaltende arzneistoffzusammensetzung
ATE100708T1 (de) Unbeschichtete pharmazeutische reaktionstablette.
KR870003781A (ko) 지효성 조성물
YU45915B (sh) Osnovna smesa za nosač terapeutski aktivnog medikamenta
CA2027592A1 (en) Solid pharmaceutical preparations of active form of vitamin d_ of improved stability
JPS5620509A (en) Long-acting pharmaceutical preparation for nasal cavity use, and method for manufacturing the same
MY118371A (en) Tetrahydrolipstatin containing compositions
ES509647A0 (es) Procedimiento para preparar una polilactida.
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
NO841518L (no) Delbare tabletter med forsinket frigjoering av virkestoff, og fremgangsmaate for fremstilling derav
MY100998A (en) Pharmaceutical formulations
DK624287A (da) Komprimeret tablet eller kapsel
NZ222110A (en) Therapeutic powder form of spray-dried acetaminophen which includes ethyl cellulose and colloidal silica, and solid pharmaceutical dosage forms comprising the powder
ES2058651T3 (es) Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
ATE158172T1 (de) Pulverförmige pharmazeutische zusammensetzung
ATE84221T1 (de) Arzneimittel mit methylcellulose.
DE69120536D1 (de) Arzneimittel
YU47573B (sh) Postupak za dobivanje čvrstog farmaceutskog preparata
GB1327560A (en) Effervescent pharmaceutical preparations
ES2059615T3 (es) Empleo del derivado de tiazol tiprotimoda para la preparacion de un agente para la terapia de infecciones por virus.

Legal Events

Date Code Title Description
PUP Patent expired